• Denosumab Treatment in CKD Patients at High Risk of Fracture

  NCT05692297

  Unknown statusInterventionalNot ApplicableUpdated Jan 25, 2023
• Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

  NCT05866029

  RecruitingInterventionalNot ApplicableUpdated Jan 12, 2026
• Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

  NCT03457818

  TerminatedInterventionalPhase 2Updated Jul 3, 2024
• Denosumab China Phase III Study

  NCT02014467

  CompletedInterventionalPhase 3Updated Oct 31, 2016
• The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity

  NCT07271771

  RecruitingInterventionalPhase 4Updated Dec 15, 2025
• Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa

  NCT02567279

  TerminatedInterventionalPhase 3Updated Jan 7, 2019

ClinicalTrials.gov ID

NCT07063797

Lead Sponsor

Peking Union Medical College HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

358Estimated

Last Update Posted

Jan 21, 2026Actual

Start Date

Feb 1, 2026Estimated

Primary Completion Date

Jul 31, 2027Estimated

Completion Date

Jul 31, 2027Estimated

Official Title

Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes

Brief Summary

This study will conduct a randomized controlled trial targeting patients with type 2 diabetes and a high risk of fractures. The aim is to evaluate the intervention effect of denosumab combined with edilossobulin on patients with a high risk of osteoporotic fractures due to type 2 diabetes, as well as its impact on bone density, bone turnover indicators, the risk of new fractures, and the risk of hypocalcemia. This will provide scientific evidence for clinical diagnosis and treatment, and offer important clinical research evidence for formulating national health policies.

• Type 2 Diabetes
• Osteoporosis
• Fractures

• Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients
• Denosumab combined with eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Confirmed diagnosis of type 2 diabetes (based on the "China Guidelines for the Prevention and Treatment of Diabetes (2024 Edition)").
2. Males aged ≥50 years; females aged ≥45 years and postmenopausal for more than 2 years.
3. Duration of diabetes >10 years; or presence of at least one of the following conditions: ①diabetic retinopathy; ②urine albumin-to-creatinine ratio (UACR)≥ 30 mg/g; ③estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m²; ④coronary atherosclerotic heart disease; ⑤ischemic stroke; ⑥transient ischemic attack; ⑦ atherosclerosis of the carotid, cerebral, or lower-extremity arteries with ≥50% luminal stenosis.
4. Glycated hemoglobin (HbA1c) ≤ 8.0 % measured within 1 month
5. History of hip or vertebral fragility fractures; or history of fragility fractures at other sites (excluding the skull, feet, and hands) with a T-score of <-1.0 at the femoral neck, total hip, or any L1-L4 site; or a T-score of <-2.0 at the femoral neck, total hip, or any L1-L4 site.
6. In the BMD measurement at lumbar vertebrae L1-L4, at least two or more vertebral bodies must meet the evaluable criteria.
7. Signed informed consent form, willing to participate in the study

Exclusion Criteria:

1. Diseases that cause secondary osteoporosis: a. Various metabolic bone diseases, such as osteomalacia, primary hyperparathyroidism, osteogenesis imperfecta, Paget's disease, etc.; b. Cushing's syndrome; c. Hyperprolactinemia; d. Others;
2. Malignant tumors within the past 5 years, except for those expected to be cured after treatment (e.g., completely resected in situ basal cell or squamous cell carcinoma of the skin, cervical cancer, or ductal carcinoma of the breast);
3. Received intravenous bisphosphonate treatment within the past 2 years or oral bisphosphonate treatment within the past 1 year;
4. History or current diagnosis of osteomyelitis or osteonecrosis of the jaw; unhealed dental or oral surgical wounds; acute dental or jaw conditions requiring oral surgery; planned to undergo invasive dental surgery during the study period;
5. Received denosumab, teriparatide, or romosozumab treatment within the past 6 months;
6. Continuous use of calcitonin for more than 3 months within the past year;
7. Use of glucocorticoids (equivalent to>5 mg/day prednisone) for more than 10 days within the past 6 weeks;
8. 25-hydroxyvitamin D<10ng/mL;
9. Active infections requiring systemic treatment;
10. Uncontrolled comorbidities, including New York Heart Association (NYHA) functional class III or above heart failure, severe arrhythmias, severe hepatic insufficiency (alanine aminotransferase or aspartate aminotransferase>3 times the upper limit of normal), severe renal insufficiency (eGFR<30 ml/min/1.73 m²);
11. Hypocalcemia, hypercalcemia, or hypercalciuria (Note: hypercalciuria is defined as a urinary calcium/creatinine ratio > 0.5 mg/mg, or 24-hour urinary calcium > 7.5 mmol).;
12. Allergy to the study drug;
13. Currently participating in other clinical trials of drugs;
14. Subjects deemed unsuitable for enrollment in this study by the investigator.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Peking Union Medical College HospitalOTHER

maoli_mail@126.com13651540858

hyn_hyn0216@126.com13667009985